All In Biotech

Drug Trial Radar · NCT04429191

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

A Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation & Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jul 8, 2020

Primary completion

Jun 13, 2023

Study completion Jun 13, 2023

Sponsor

Lead sponsor
Jasper Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

Conditions

  • MYELODYSPLASTIC SYNDROME; MDS
  • ACUTE MYELOID LEUKEMIA; AML

Interventions

  • Humanized anti-CD117 Monoclonal Antibody (JSP191)Biological

    Procedure: single intravenous infusion of JSP191 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects experiencing adverse events and serious adverse events will be assessed.Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)
  2. The number of dose limiting toxicities will be assessed.Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)
  3. The type of dose limiting toxicities will be assessed.Time frame: Up to 1 year post Donor Cell Transplant (28 days dose limiting toxicity period)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Stanford University

    Stanford, California

  • Rush University Medical Center

    Chicago, Illinois

  • Oregon Health & Science University

    Portland, Oregon

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.